Soranamo 200 mg contains Sorafenib, an oral multikinase inhibitor used primarily for the treatment of advanced hepatocellular carcinoma (liver cancer), renal cell carcinoma (kidney cancer), and differentiated thyroid carcinoma. Sorafenib works by blocking tumor cell proliferation and tumor angiogenesis, helping to slow cancer progression.

Mechanism of Action

• Sorafenib inhibits multiple tyrosine kinases, including:

  • Raf kinases (affecting tumor cell proliferation)

  • VEGFR-1, VEGFR-2, VEGFR-3 (affecting angiogenesis)

  • PDGFR-β and other kinases involved in tumor growth

• By blocking these pathways, Sorafenib reduces tumor blood supply and inhibits cancer cell growth, leading to slowed tumor progression.

  Uses

  • Treatment of advanced hepatocellular carcinoma (HCC).

  • Treatment of advanced renal cell carcinoma (RCC).

  • Treatment of differentiated thyroid carcinoma not responsive to radioactive iodine.

  • Used in patients with unresectable or metastatic tumors.

    Adverse Effects

    • Fatigue, weakness

    • Diarrhea, nausea, or vomiting

    • Hand-foot syndrome (redness, pain, or peeling of palms/soles)

    • High blood pressure (hypertension)